Estimated Control (100%) Closed Transaction verified GlaucomaOphthalmic PharmaceuticalsOphthalmologyPharmaPharmaceuticals
Aerie Pharmaceuticals, Inc. acquired by Alcon Research, Ltd.
Alcon Research, Ltd. acquired Aerie Pharmaceuticals, Inc., an US ophthalmic pharmaceuticals brand on Aug 22, 2022. The transaction value is shown as USD 750m. The current comp implies EV / revenue of 4.4x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- Aerie Pharmaceuticals, Inc.
- Acquirer
- Alcon Research, Ltd.
- Seller
- Aerie Pharmaceuticals, Inc. shareholders
- Announced
- 2022-08-22
- Geography
- United States
- Tags
- GlaucomaOphthalmic PharmaceuticalsOphthalmologyPharmaPharmaceuticals
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- 100%
- First added
- 2026-08-08
- Latest update
- 2026-08-08
Value and multiples
Price / value
USD 750M
Enterprise Value | USD
Basis: Public source
EV / revenue
4.4x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- USD 750m enterprise value is treated as publicly disclosed or derived directly from public source data.
- EV / revenue is shown as 4.4x based on the available comp inputs.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
Source summary
No public source summary has been published for this transaction yet.